France· FR:62004984
ADAKVEO 10 mg/mL, solution à diluer pour perfusion
A crizanlizumab product, registered in France by NOVARTIS EUROPHARM (IRLANDE). The same ATC class is registered in 7 of our 19 countries.
Checked against Base de données publique des médicaments — BDPM (France) on
Informational only — not a medical device.
Where it is registered
Crizanlizumab is registered in 7 of 19 countries.
Countries holding a registration under ATC B06AX01 (crizanlizumab), each read from that country’s own register.
- This record: France, from Base de données publique des médicaments — BDPM (France)
- 6 of them publish a price we can compare per daily dose
Crizanlizumab · ATC B06AX01
7 / 19 countries
- Belgiumprice
- Finlandprice
- Franceprice
- Polandprice
- Spainprice
- United Kingdom
- United Statesprice
The record
At a glance
Base de données publique des médicaments — BDPM (France)- Manufacturer
- NOVARTIS EUROPHARM (IRLANDE)
- Country
- France (FR)
- ATC code
- B06AX01
- ATC class
- Crizanlizumab
- Defined daily dose
- 12.5 mg, P
- Reimbursed
- No
- Source register
- Base de données publique des médicaments — BDPM (France)
- Last checked
- September 12, 2026
Packs & prices · 1
- cip1334009550755301 flacon(s) en verre de 10 ml
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Crizanlizumab in 5 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United StatesADAKVEONovartis Pharmaceuticals Corporation
- BelgiumAdakveo 10 mg/mlNovartis Europharm
- SpainADAKVEO 10 MG/ML CONCENTRADO PARA SOLUCION PARA PERFUSIONNovartis Europharm Limited
- FinlandAdakveoNovartis Europharm Limited
- United KingdomAdakveo 100mg/10ml concentrate for solution for infusion vialsNovartis Pharmaceuticals UK Ltd
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/501118d3-e112-4346-8dcb-5ff3a177e930 GET /v1/drugs/501118d3-e112-4346-8dcb-5ff3a177e930?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"cis": "62004984",
"date_amm": "2020-10-28",
"type_amm": "Procédure centralisée",
"numero_ue": "EU/1/20/1476",
"statut_amm": "Autorisation retirée",
"statut_bdm": "Alerte",
"forme_pharmaceutique": "solution à diluer pour perfusion",
"voies_administration": "intraveineuse",
"etat_commercialisation": "Non commercialisée",
"surveillance_renforcee": "Oui"
}See everything about crizanlizumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.